In this letter, we share our concerns regarding fluctuations of homozygosity for ApoE/ε4 allele. It appeared that over time, expression of this gene raised the felled as reported by various researchers. Considering the diversity of phenotypic characteristics assigned to expression of ApoE/ε4, seems to be a potentially useful to direct practitioner on concrete figures related to the genetic propensity of many conditions, from circulatory to mental disorders.
We find the following issue so peculiar that we need to bring surface our cocerns. This matter rose out upon an attempt to pursue a comment on a review paper on allele frequencies of the apolipoprotein E (ApoE) ɛ4 predisposing Alzheimer's disease (AD) triggered by chronic traumatic encephalopathy (CTE).
This allele is associated with increased cholesterol levels and inheritance of the early-onset AD. We have been confused by some conclusions claimed in, otherwise gladly cited, review [3] . Besides of 48 CTE cases elaborated in the literature review, authors of that same article report three own cases. That sufficed to conclude that 15% of the general population is carriers of the ApoE/ε4 allele [3] . Homozygosity in the general population was estimated to be 3%, contrasting 15% of the homozygosity among patients with AD.
Eight years before, Yoshida et al. evaluated findings upon autopsies [4] attaching frequency of this allele to nearly 30% of the general population, and 45% to 60% of patients with AD. Even Hollingworth et al. [2] put heterozygosity for this gene in the general population to be this high. Consequently, it seems the general population closely resembles the population in paper subject. What, finally, supports [1] the number providently suggested years ago [3] . Masking such an important hypothesis in a review article written years before some other sources with similar epidemiology seems a bit doubtful.
When we authored this paper, it was not our intention to criticize, but to follow up in a constructive manner and produce a creative debate on the subject. Whereas McKee et al. [3] might not feel that the ɛ4 prevalence rate in AD is relevant to their findings on CTE; they astonish by referring to Eisenberg et al., though the late paper is newer than paper subject is [1] .
Regardless of the sympathy and our preference towards review article of McKee et al, [3] epidemiological data used by Eisenberg et al. [1] should be set forth as a reference, even not verbatim.
Indicating a discrepancy in data about the prevalence of ApoE/ɛ4, rather than presenting any data, extenuates our contribution to the science, but not to the literature as relevance of our paper is to anyone trying to connect ApoE/ɛ4, CTE, and AD. Thus, this letter could be accepted as a "cry for accurate information" from a confused practitioner.
